Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.

Literature DB >> 22424602

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.

Nina D Wagner-Johnston, Nancy L Bartlett, Amanda Cashen, Joseph R Berger.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 2012 PMID： 22424602 DOI： 10.3109/10428194.2012.676170

Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022

Keyword Cloud
Cited

× No keyword cloud information.

19 in total

Review 1. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

Authors: Sagun D Goyal; Nancy L Bartlett
Journal: Curr Hematol Malig Rep Date: 2012-09 Impact factor: 3.952

2. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors: Salim Chahin; Joseph R Berger
Journal: J Neurovirol Date: 2014-11-18 Impact factor: 2.643

Review 3. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

Authors: Fariha Zaheer; Joseph R Berger
Journal: Ther Adv Drug Saf Date: 2012-10

Review 4. The double-edged sword: Neurotoxicity of chemotherapy.

Authors: Rajiv S Magge; Lisa M DeAngelis
Journal: Blood Rev Date: 2014-09-28 Impact factor: 8.250

5. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors: Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal: Cancer Date: 2014-04-25 Impact factor: 6.860

Review 6. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Authors: Geetika Bhatt; Kami Maddocks; Beth Christian
Journal: Curr Hematol Malig Rep Date: 2016-12 Impact factor: 3.952

7. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.

Authors: Dennis W Raisch; John A Rafi; Cheng Chen; Charles L Bennett
Journal: Expert Opin Drug Saf Date: 2016-06-20 Impact factor: 4.250